GM-CSF Antibody

Recombinant Human GM‑CSF (Catalog # 215-GM) stimulates proliferation in the TF‑1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human GM‑CSF (0.5 ng/mL) is neutralized (green line) by increasing concentrations of Human GM‑CSF Polyclonal Antibody (Catalog # AB-215-NA). The ND50 is typically 1-6 µg/mL.

• Reactivity: Hu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

GM-CSF Antibody Summary

• Immunogen: E. coli-derived recombinant human GM-CSF
  Ala18-Glu144
  Accession # P04141
• Specificity: Detects human GM-CSF in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) G-CSF, rhIL‑1 alpha , rhIL-1 beta , rhIL-2, rhIL-3, rhIL-4, rhIL-6, rhTNF-alpha or rhTNF-beta is observed. Neutralizes the biological activity of both rhGM-CSF and natural human GM-CSF. It will not neutralize the biological activity of recombinant mouse GM-CSF.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: CSF2
• Purity Statement: Protein A or G purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 1-6 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 1 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for GM-CSF Antibody

• colony stimulating factor 2 (granulocyte-macrophage)
• Colony-stimulating factor
• CSF
• CSF2
• CSF-2
• GMCSF
• GM-CSF
• GMCSFgranulocyte-macrophage colony-stimulating factor
• granulocyte-macrophage colony stimulating factor
• MGC131935
• MGC138897
• Molgramostim
• molgramostin
• Sargramostim

Background

GM-CSF was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils (1, 2). GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity (3‑5). It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines (6, 7). The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha ‑helices (8‑12). Mature human GM-CSF shares 63%‑70% amino acid sequence identity with canine, feline, porcine, and rat GM-CSF and 54% with mouse GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta  chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 (13, 14). In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha (15). Human GM-CSF is active on canine and feline cells but not on murine cells (16‑18).

1. Martinez-Moczygemba, M. and D.P. Huston (2003) J. Allergy Clin. Immunol. 112:653.
2. Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.
3. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
4. Cao, Y. (2007) J. Clin. Invest. 117:2362.
5. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
6. Heuser, M. et al. (2007) Semin. Hematol. 44:148.
7. Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
8. Kaushansky, K. et al. (1992) Biochemistry 31:1881.
9. Diederichs, K. et al. (1991) Science 254:1779. 
10. Cantrell, M.A. et al. (1985) Proc. Natl. Acad. Sci. 82:6250.
11. Lee, F. et al. (1985) Proc. Natl. Acad. Sci. 82:4360.
12. Wong, G.G. et al. (1985) Science 228:810.
13. Onetto-Pothier, N. et al. (1990) Blood 75:59.
14. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655.
15. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
16. Hogge, G.S. et al. (1990) Cancer Gene Ther. 6:26.
17. Sprague, W.S. et al. (2005) J. Comp. Pathol. 133:136.
18. Shanafelt, A.B. et al. (1991) J. Biol. Chem. 266:13804.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for GM-CSF Antibody (AB-215-NA)(1)

Publication using AB-215-NA

• Solanilla A, Dechanet J, El Andaloussi A, Dupouy M, Godard F, Chabrol J, Charbord P, Reiffers J, Nurden AT, Weksler B, Moreau JF, Ripoche J CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells. Blood, 2000-06-15;95(12):3758-64. 2000-06-15 [PMID: 10845907] (Neutralization, Human)

Bioinformatics

• Gene Symbol: CSF2
• Uniprot:
  • P04141(Human)